All In Biotech

Drug Trial Radar · NCT06299319

Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD

Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Sep 1, 2024

Primary completion

Sep 4, 2026

Study completion Sep 4, 2026

Sponsor

Lead sponsor
Centre for Addiction and Mental HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. There is interest to see if similar effects may be provided in those with obsessive compulsive disorder (OCD). The purpose of this study is to evaluate the safety, feasibility, and clinical effects of psilocybin administration in those with OCD. Ten participants with treatment-resistant OCD will receive two doses of 25mg of psilocybin under supportive conditions, two weeks apart. The investigators hypothesize that two sessions of psilocybin 25mg administered under supportive conditions to participants with treatment-resistant OCD will lead to significant reductions in OCD symptoms.

Conditions

  • Obsessive-Compulsive Disorder

Interventions

  • PsilocybinDrug

    The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered twice during the trial, in conjunction with supportive therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility of administering psilocybin (25 mg) in adults with treatment-resistant OCDTime frame: Screening Period, Intervention (2 weeks), Follow-up after 2nd dosing session (up to 10 weeks after 2nd dose)
  2. Incidence of adverse events (Safety and Tolerability)Time frame: Screening Period, Intervention (2 weeks), Follow-up after 2nd dosing session (up to 10 weeks after 2nd dose)
  3. Change in the Yale-Brown Obsessive-Compulsive Scale (YBOCS) total score from baselineTime frame: Baseline (Day -1) to Week 3 (Day 21)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Addiction and Mental Health

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.